IPD.ASX: Quarterly Activities Report and Appendix 4C - Dec-2024 Qtr

Quarterly Activities Report and Appendix 4C - Dec-2024 Qtr

Stock	Impedimed Ltd (IPD.ASX)
Release Time	31 Jan 2025, 8:24 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

ImpediMed reports record revenue and cash receipts in Q2 FY25

Key Points

Record revenue of A$3.3m, up from A$2.7m in Q1 FY25
Record cash receipts of A$3.4m, up from A$2.7m in Q1 FY25
Net operating cash outflows reduced to A$2.5m from A$4.8m in Q1 FY25

Full Summary

ImpediMed Limited (ASX:IPD) has released its Quarterly Activities Report and Appendix 4C Cash Flow Report for the quarter ending 31 December 2024 (Q2 FY25). The company reported record unaudited total revenue of A$3.3 million for the quarter, up from A$2.7 million in the previous quarter (Q1 FY25). The increase was driven by distributor inventory restocking and a weakening of the Australian dollar against the US dollar. ImpediMed also recorded record cash receipts from customers of A$3.4 million, up from A$2.7 million in Q1 FY25. Net operating cash outflows for the quarter were A$2.5 million, a reduction from A$4.8 million in the previous quarter. This was due to the positive impact of the R&D tax credit received and the timing of administration costs. The company's core business Total Contracted Value (TCV) signed during the quarter was A$3.2 million, compared to A$4.8 million in Q1 FY25. The reduction was attributed to a lower number of units due for renewal and fewer new units sold. However, the company noted continued strong price increases on renewals, averaging 23% in the quarter. ImpediMed's cash balance at the end of the quarter was A$17.7 million.